Active CD38 protein-coupled magnetic Beads

Cat.No. : CD38-4314M
  • Specification
  • Gene Information
  • Related Products
  • Download
Species : Human
Appearance : Powder mixture
Particle size : 2 μm
Source : HEK293
Protein length : Val 43 - Ile 300
Bio-activity : Immobilized 26.6 μg CD38 protein to 1 mg Beads, can bind the Anti-CD38 Antibody with an EC50 of 0.9196 μg/mL.
Coupled amount of protein : ≈818 pmol (26.6 μg) CD38/mg Beads
Capacity : >133 pmol (20 μg) antibody/mg beads
Formulation : PBS, pH7.4, with 10% Trehalose
Reconstitution : 2 mL sterile deionized water (1 mg beads/mL)
Background : The biotinylated CD38 protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-CD38 antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This CD38 coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.
Application : This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
Storage : Upon receipt, please store the Beads at -20°C for 1 year in lyophilized state.

Not For Human Consumption!

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
01/15/2021

    By employing this protein reagent, I can swiftly obtain sufficient protein samples, meeting the high demand for experiments.

    06/11/2019

      The consumable costs associated with this protein reagent are relatively low, rendering it economically feasible and efficient for large-scale applications in the laboratory.

      06/08/2019

        A magical partner in experimentation, taking your research to new heights.

        Q&As (7)

        Ask a question
        What are the challenges and future directions in CD38 research? 04/06/2023

         CD38 research faces several challenges and offers exciting future directions. One challenge is deciphering the precise molecular mechanisms by which CD38 modulates cellular processes and interacts with other proteins. Additionally, understanding the context-dependent functions of CD38 in different cell types and disease conditions requires further investigation. Future directions include exploring the therapeutic potential of CD38 inhibitors in combination with other treatment modalities, investigating the role of CD38 in the tumor microenvironment, and advancing our understanding of the dynamic regulation of CD38 expression and activity. Such advancements will pave the way for personalized medicine approaches targeting CD38 in various diseases.

        What are the functions and mechanisms of protein CD38 in biological systems? 02/15/2023

        Protein CD38 is a transmembrane enzyme that plays a crucial role in various biological processes. Its main function is the hydrolysis of NAD+ to generate ADP-ribose, leading to the production of cyclic ADP-ribose (cADPR) and ADP-ribose (ADPR) as intracellular calcium signaling molecules. CD38 is involved in regulating cell proliferation, apoptosis, and immune responses. Its mechanisms of action include modulation of intracellular signaling pathways, such as cADPR-mediated calcium release and involvement in apoptotic pathways through ADPR.

        Does CD38 interact with other proteins or signaling pathways? 01/08/2023

        Yes, CD38 exhibits interactions with several proteins and signaling pathways. For instance, CD38 is involved in the regulation of calcium signaling by interacting with calcium channels and receptors. It also interacts with other proteins in the NAD+ metabolism pathway, such as NAD+-consuming enzymes and NAD+ synthesizing enzymes. Furthermore, CD38 can modulate immune responses by interacting with immune cell receptors and co-stimulatory molecules. Understanding these protein-protein interactions and their functional consequences is essential for comprehending the broader role of CD38 in cellular processes and disease pathogenesis.

        What are the current areas of research focus regarding CD38? 12/08/2022

        Current research on CD38 encompasses various aspects. One area of focus is elucidating the role of CD38 in disease pathogenesis, including its involvement in cancer progression, autoimmune disorders, and neurodegenerative diseases. Researchers are also investigating the potential of CD38 as a diagnostic and prognostic marker in different diseases. Additionally, efforts are being made to identify novel therapeutic targets within the CD38 signaling pathway and develop more effective and specific CD38 inhibitors. Understanding the complex regulatory mechanisms and functional consequences of CD38 will contribute to the development of targeted therapies and precision medicine approaches.

        Are there any genetic variations or polymorphisms associated with CD38 expression or function? 11/22/2022

        Yes, genetic variations in the CD38 gene have been identified, and some of these variations have been associated with altered CD38 expression or function. For example, certain single nucleotide polymorphisms (SNPs) in the CD38 gene have been linked to changes in CD38 enzyme activity and NAD+ metabolism. These genetic variations can influence immune responses, susceptibility to certain diseases, and response to therapies targeted at CD38.

        In which cell types is CD38 expressed and considered important? 01/11/2020

        CD38 is widely expressed in various cell types, including immune cells (such as lymphocytes, monocytes, dendritic cells, etc.), neuronal cells, endothelial cells, and several others. It is especially important in immune cells, where it plays a critical role in immune responses, such as T cell activation, B cell differentiation, and antibody production. CD38 expression in neuronal cells has been linked to neurotransmitter release and synaptic plasticity. Additionally, CD38 expression in endothelial cells is associated with regulating vascular function and inflammation.

        What are the potential therapeutic implications of targeting CD38? 06/17/2016

        Targeting CD38 has gained significant attention in the development of therapeutic strategies. CD38 inhibitors, such as monoclonal antibodies, have shown promising results in the treatment of hematological malignancies, particularly multiple myeloma. These inhibitors block CD38 enzymatic activity, leading to impaired tumor cell growth, enhanced immune responses, and induction of cell death. Moreover, CD38-targeted therapies have also been explored for autoimmune diseases and inflammatory disorders. Further research is underway to optimize CD38-targeted therapies and expand their applications in different disease settings.

        Ask a Question for All CD38 Products

        Required fields are marked with *

        My Review for All CD38 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends